Phase 2 Study of Copanlisib plus Gemcitabine and Cisplatin in Advanced CCA
Dec 19, 2023
Preliminary results of a phase 2 study suggest that the addition of the PI3K inhibitor copanlisib to chemotherapy in the first-line setting was not associated with survival benefit in patients with advanced CCA. While chemotherapy with gemcitabine and cisplatin remains the current standard of care as first-line therapy for patients with advanced CCA, survival outcomes are suboptimal with a median OS of <1 year, underscoring the need for novel approaches to improve treatment outcomes.1 Based on the rationale that PI3K/AKT activation may increase resistance to chemotherapy, it is hypothesized that inhibiting the PI3K/AKT axis may improve outcomes.
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…